Lauri Tuominen, Reetta-Liina Armio, Justine Y Hansen, Maija Walta, Nikolaos Koutsouleris, Heikki Laurikainen, Raimo K R Salokangas, Bratislav Misic, Jarmo Hietala
{"title":"Molecular, physiological and functional features underlying antipsychotic medication use related cortical thinning.","authors":"Lauri Tuominen, Reetta-Liina Armio, Justine Y Hansen, Maija Walta, Nikolaos Koutsouleris, Heikki Laurikainen, Raimo K R Salokangas, Bratislav Misic, Jarmo Hietala","doi":"10.1038/s41398-025-03336-0","DOIUrl":null,"url":null,"abstract":"<p><p>Use of antipsychotic medication is related to thinning of the cerebral cortex, but the underlying mechanisms of this effect remain largely unknown. Here, we investigated potential mechanisms across multiple levels of description by comparing antipsychotic medication related cortical thinning to atlases of normative neurotransmitter distributions, structural and functional organization of the brain, and meta-analyses of functional activation from the Neurosynth database. We first analyzed a single-site discovery sample of patients (N = 131) with early psychosis for whom antipsychotic related cortical thinning was estimated based on lifetime exposure to antipsychotics. Findings were replicated using data from a large (N ≥ 2168) ENIGMA meta-analysis on schizophrenia patients. We discovered that antipsychotic related cortical thinning is associated with a number of neurotransmitter systems, most notably the serotonin system, as well as physiological measures, functional networks and neural oscillatory power distributions typical for regions subserving higher cognition. At the functional level, antipsychotic related cortical thinning affects regions involved in executive function and motivation, but not perception. These results show how molecular, physiological, and large-scale functional patterns may underlie antipsychotic related cortical thinning.</p>","PeriodicalId":23278,"journal":{"name":"Translational Psychiatry","volume":"15 1","pages":"129"},"PeriodicalIF":5.8000,"publicationDate":"2025-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11973188/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational Psychiatry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41398-025-03336-0","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PSYCHIATRY","Score":null,"Total":0}
引用次数: 0
Abstract
Use of antipsychotic medication is related to thinning of the cerebral cortex, but the underlying mechanisms of this effect remain largely unknown. Here, we investigated potential mechanisms across multiple levels of description by comparing antipsychotic medication related cortical thinning to atlases of normative neurotransmitter distributions, structural and functional organization of the brain, and meta-analyses of functional activation from the Neurosynth database. We first analyzed a single-site discovery sample of patients (N = 131) with early psychosis for whom antipsychotic related cortical thinning was estimated based on lifetime exposure to antipsychotics. Findings were replicated using data from a large (N ≥ 2168) ENIGMA meta-analysis on schizophrenia patients. We discovered that antipsychotic related cortical thinning is associated with a number of neurotransmitter systems, most notably the serotonin system, as well as physiological measures, functional networks and neural oscillatory power distributions typical for regions subserving higher cognition. At the functional level, antipsychotic related cortical thinning affects regions involved in executive function and motivation, but not perception. These results show how molecular, physiological, and large-scale functional patterns may underlie antipsychotic related cortical thinning.
期刊介绍:
Psychiatry has suffered tremendously by the limited translational pipeline. Nobel laureate Julius Axelrod''s discovery in 1961 of monoamine reuptake by pre-synaptic neurons still forms the basis of contemporary antidepressant treatment. There is a grievous gap between the explosion of knowledge in neuroscience and conceptually novel treatments for our patients. Translational Psychiatry bridges this gap by fostering and highlighting the pathway from discovery to clinical applications, healthcare and global health. We view translation broadly as the full spectrum of work that marks the pathway from discovery to global health, inclusive. The steps of translation that are within the scope of Translational Psychiatry include (i) fundamental discovery, (ii) bench to bedside, (iii) bedside to clinical applications (clinical trials), (iv) translation to policy and health care guidelines, (v) assessment of health policy and usage, and (vi) global health. All areas of medical research, including — but not restricted to — molecular biology, genetics, pharmacology, imaging and epidemiology are welcome as they contribute to enhance the field of translational psychiatry.